Project Grant HT94252411117
Award Date
9/30/24
Completion Date
9/29/26
Dollars Obligated
$1.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This $3,580,840 federal Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, will fund the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K" project at the University of Sydney in Australia. The project aims to improve prostate cancer outcomes in Africa through advancements in precision health approaches. The University of Sydney, as the prime awardee, will leverage its expertise in cancer research, drug...
The University of Pretoria in South Africa was awarded a $738,775 Project Grant under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) to conduct the "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA" research project. The grant, effective from September 30, 2024 to March 13, 2025, supports advanced biomedical research focused on transforming...
This federal Project Grant award, valued at $1,235,845.00, was provided by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the University of Illinois to leverage data science methods to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The grant, with a performance period from August 15, 2025 to August 14, 2028, supports advanced biomedical research initiatives focused on transforming healthcare for military service...
The federal Project Grant award in the amount of $473,463 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled the "Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium," is being used by Covenant University, a private university in Nigeria, to conduct advanced biomedical research focused on investigating cancer care and outcomes for Black men. The grant was awarded on September 30,...
This $1,323,505 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to explore immune-tumor cell metabolic interactions in prostate cancer among African American men. The grant recipient, Trustees of Indiana University, will leverage its expertise in biomedical sciences and public health to conduct this innovative research initiative. The award has a performance period from August 1, 2024 to July 31, 2027....
The Defense Health Agency awarded a $1,346,633 Project Grant to the George Washington University under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research titled "A PRIMARY ROLE FOR THE CIRCULATORY MICROENVIRONMENT IN AFRICAN AMERICAN PROSTATE CANCER DISPARITIES?" from May 15, 2023 to May 14, 2026. As the prime awardee, George Washington University will investigate medical solutions for prostate cancer disparities affecting African...
This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...
This federal Project Grant award for $468,672 was made by the Defense Health Agency on September 30, 2024 under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award, titled "The Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium", is to support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The award involves two sub-awards to academic research...
This $241,500 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund research at Duke University to understand the molecular communication between different prostate cancer cell types. The research aims to transform healthcare for military service members and the broader public by advancing the scientific understanding of prostate cancer. The award term is from September 1, 2025 to August 31, 2027. Duke...
This federal Project Grant award of $785,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports mechanism-centric predictive modeling research for prostate cancer at Rutgers, The State University of New Jersey. The research aims to develop innovative approaches for improving diagnosis, treatment, and outcomes for military personnel and the public impacted by prostate cancer. Over the performance period from July 1, 2024...